Physician profile
Alejandro Perez
NPI 1497216535
$1,681.48
in general payments reported to CMS, 2019-2025
11 companies · $821 in 2025
The $821 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $112 · 2023: $105 · 2024: $644 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463 · Education: $2.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.72 |
| Education | $2.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.73 | 2024-2025 | |
| Gilead Sciences, INC. | $232.65 | 2024 | Veklury |
| Shionogi INC | $141.66 | 2025 | Fetroja |
| Viiv Healthcare Company | $135.15 | 2024-2025 | Dovato, Cabenuva |
| Insmed, INC. | $84.62 | 2025 | Brinsupri, Arikayce |
| Theratechnologies INC. | $69.64 | 2025 | Egrifta, Trogarzo |
| Aimmune Therapeutics, INC. | $54.56 | 2025 | Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $49.64 | 2025 | Livtencity |
| Melinta Therapeutics, LLC | $26.94 | 2025 | Rezzayo, Orbactiv |
| Merck Sharp & Dohme LLC | $23.63 | 2025 | Zerbaxa, Prevymis |
| Paratek Pharmaceuticals, INC. | $16.77 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.